Cardiotoxicity from cancer treatment

Cardiotoxicity from cancer treatment means damage to the heart or its function caused by cancer treatments such as chemotherapy, immunotherapy or radiation. A 2025 review says these treatments have increased survival but are frequently linked to cardiovascular toxicity, which has a significant impact on outcomes and well-being. The review says the changes can lead to conditions such as cardiomyopathy and can result in heart failure and sudden cardiac death.

Also called Cancer therapy-related cardiovascular toxicity · Cardiotoxicity

  • Condition
  • In this atlas

Overview

Technical summary

MeSH Cardiotoxicity (D066126) is recorded as a broad match: its scope note covers damage to the heart from toxic substances, including chemotherapy, immunotherapy and radiation, and is not limited to cancer care. The description rests on that scope note and on a 2025 review under a CC BY licence (Heart Failure Reviews). The review says there is no universally accepted definition and that the condition is often defined clinically as a reduction in left ventricular ejection fraction. Drug names, risk factors, monitoring and protective strategies in the review are not repeated here. The evidence is descriptive and comes from a narrative review, with no trial data.

Classification codes

  • MeSH MeSH linked-data descriptor record fetched on 2026-11-18, lastUpdated 2019-07-05; the record states no yearly MeSH release D066126

Burden

No burden claims are published.

Claims and evidence

Context People treated for cancer with chemotherapy, targeted therapy, immunotherapy or radiotherapy (narrative review)

Recipient
Recipient not specified
Population
People who have had cancer treatment such as chemotherapy, targeted therapy, immunotherapy or radiotherapy, as the review describes them. The review also mentions long-term studies of childhood cancer survivors.
Care setting
Cancer treatment and cardio-oncology care, as described in the review.
Geography
Not stated for the review as a whole.
Life stage
Adults and children are not separated here. This record makes no statement about pregnancy, newborns or children.
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (a description of a condition).
Eligibility: 1 inclusion criterion; exclusion criteria not stated
Included
  • Having had cancer treatment that can harm the heart
Excluded
None stated
  • Description Evidence synthesis Certainty not assessed

    MeSH describes cardiotoxicity as damage to the heart or its function after exposure to toxic substances such as chemotherapy drugs, immunotherapy or radiation. A 2025 narrative review (Heart Failure Reviews) says cancer treatments are frequently linked to cardiovascular toxicity with a significant impact on clinical outcomes and well-being, that there is no universally accepted definition of the condition (it is often defined clinically as a reduction in left ventricular ejection fraction), and that the changes can lead to dilated and restrictive cardiomyopathy and can result in heart failure and sudden cardiac death.

    Applies to Recipient not specified People treated for cancer with chemotherapy, targeted therapy, immunotherapy or radiotherapy (narrative review)

    Certainty method
    Not assessed
    Limitations
    A narrative review and a thesaurus scope note, not a study of how often the damage occurs. The MeSH descriptor is not limited to cancer care. The review gives no risk figures here: its drug names, mechanisms, risk estimates, classification, monitoring and protective strategies are not repeated, and nothing here says who should be monitored or how.
    Last checked
    2026-11-18
    Next evidence check due
    Not scheduled
    Sources and citations (7)
    1. Supports MeSH scope note for descriptor D066126 (Cardiotoxicity)

      Dataset · U.S. National Library of Medicine · Edition MeSH linked-data record of the preferred concept M0592728 of descriptor D066126, fetched 2026-11-18. The scope note is on this concept record, not on the descriptor record. · MeSH: M0592728

      Locator
      scopeNote.@value, sentence 1
      How it applies
      MeSH scope note: heart damage from chemotherapy, immunotherapy or radiation.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      f80e554a493c601a68a23f9ff8b6f60bc0310dc074bd769961c0d895b865f807
      Reuse basis
      The NLM web policies page (sha256 c8b7026b5c3fcfd1b0cb88755077f6a99a5f2159eecd42b0e7d1a5ad9b30ec55, hash only) says works produced by the U.S. government are not subject to copyright protection in the United States and asks users to acknowledge NLM as the source. The NLM MeSH terms and conditions page (sha256 f33b14141a5b6c8a2b1464c751dbdbb0a0d476c913851bf2a8c3d5c14b1afce7, hash only) asks redistributors to maintain current data or to make known that their copy may not reflect the most current data. This copy was fetched on 2026-11-18 and may not reflect the most current data. The raw bytes are committed in the atlas repository.
    2. Supports Cancer therapy-induced cardiotoxicity: mechanisms and mitigations

      Publication · Heart Failure Reviews · Edition PMC Open Access subset full-text XML, from NCBI E-utilities (Heart Failure Reviews, 2025), fetched 2026-11-18. A narrative or literature review. Used only for how the review defines cardiotoxicity from cancer treatment, what it links to and what it says about the heart conditions that can follow; its drug names, mechanisms, risk figures and cardioprotective strategies are not used. · PMCID: PMC12297282 · PMID: 40481994 · DOI: 10.1007/s10741-025-10531-0

      Locator
      Abstract, sentence 2
      How it applies
      Cancer treatments are frequently linked to cardiovascular toxicity.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      1fd62c1ddd41f65aceb23e6c727e3a74174e9abddfb6e23d988bce38d5a34e2c
      Reuse basis
      PMC Open Access subset article under the Creative Commons Attribution 4.0 licence (https://creativecommons.org/licenses/by/4.0/). The article's own license element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
    3. Supports Cancer therapy-induced cardiotoxicity: mechanisms and mitigations

      Publication · Heart Failure Reviews · Edition PMC Open Access subset full-text XML, from NCBI E-utilities (Heart Failure Reviews, 2025), fetched 2026-11-18. A narrative or literature review. Used only for how the review defines cardiotoxicity from cancer treatment, what it links to and what it says about the heart conditions that can follow; its drug names, mechanisms, risk figures and cardioprotective strategies are not used. · PMCID: PMC12297282 · PMID: 40481994 · DOI: 10.1007/s10741-025-10531-0

      Locator
      Introduction, para 2, sentence 2 (first part)
      How it applies
      No universally accepted definition.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      1fd62c1ddd41f65aceb23e6c727e3a74174e9abddfb6e23d988bce38d5a34e2c
      Reuse basis
      PMC Open Access subset article under the Creative Commons Attribution 4.0 licence (https://creativecommons.org/licenses/by/4.0/). The article's own license element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
    4. Supports Cancer therapy-induced cardiotoxicity: mechanisms and mitigations

      Publication · Heart Failure Reviews · Edition PMC Open Access subset full-text XML, from NCBI E-utilities (Heart Failure Reviews, 2025), fetched 2026-11-18. A narrative or literature review. Used only for how the review defines cardiotoxicity from cancer treatment, what it links to and what it says about the heart conditions that can follow; its drug names, mechanisms, risk figures and cardioprotective strategies are not used. · PMCID: PMC12297282 · PMID: 40481994 · DOI: 10.1007/s10741-025-10531-0

      Locator
      Introduction, para 2, sentence 2 (second part)
      How it applies
      Often defined clinically as a fall in ejection fraction.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      1fd62c1ddd41f65aceb23e6c727e3a74174e9abddfb6e23d988bce38d5a34e2c
      Reuse basis
      PMC Open Access subset article under the Creative Commons Attribution 4.0 licence (https://creativecommons.org/licenses/by/4.0/). The article's own license element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
    5. Supports Cancer therapy-induced cardiotoxicity: mechanisms and mitigations

      Publication · Heart Failure Reviews · Edition PMC Open Access subset full-text XML, from NCBI E-utilities (Heart Failure Reviews, 2025), fetched 2026-11-18. A narrative or literature review. Used only for how the review defines cardiotoxicity from cancer treatment, what it links to and what it says about the heart conditions that can follow; its drug names, mechanisms, risk figures and cardioprotective strategies are not used. · PMCID: PMC12297282 · PMID: 40481994 · DOI: 10.1007/s10741-025-10531-0

      Locator
      Abstract, sentence 5 (first part)
      How it applies
      The changes can lead to cardiomyopathy.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      1fd62c1ddd41f65aceb23e6c727e3a74174e9abddfb6e23d988bce38d5a34e2c
      Reuse basis
      PMC Open Access subset article under the Creative Commons Attribution 4.0 licence (https://creativecommons.org/licenses/by/4.0/). The article's own license element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
    6. Supports Cancer therapy-induced cardiotoxicity: mechanisms and mitigations

      Publication · Heart Failure Reviews · Edition PMC Open Access subset full-text XML, from NCBI E-utilities (Heart Failure Reviews, 2025), fetched 2026-11-18. A narrative or literature review. Used only for how the review defines cardiotoxicity from cancer treatment, what it links to and what it says about the heart conditions that can follow; its drug names, mechanisms, risk figures and cardioprotective strategies are not used. · PMCID: PMC12297282 · PMID: 40481994 · DOI: 10.1007/s10741-025-10531-0

      Locator
      Abstract, sentence 5 (end)
      How it applies
      The conditions can result in heart failure and sudden cardiac death.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      1fd62c1ddd41f65aceb23e6c727e3a74174e9abddfb6e23d988bce38d5a34e2c
      Reuse basis
      PMC Open Access subset article under the Creative Commons Attribution 4.0 licence (https://creativecommons.org/licenses/by/4.0/). The article's own license element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
    7. Background Cancer therapy-induced cardiotoxicity: mechanisms and mitigations

      Publication · Heart Failure Reviews · Edition PMC Open Access subset full-text XML, from NCBI E-utilities (Heart Failure Reviews, 2025), fetched 2026-11-18. A narrative or literature review. Used only for how the review defines cardiotoxicity from cancer treatment, what it links to and what it says about the heart conditions that can follow; its drug names, mechanisms, risk figures and cardioprotective strategies are not used. · PMCID: PMC12297282 · PMID: 40481994 · DOI: 10.1007/s10741-025-10531-0

      Locator
      Abstract, sentence 1
      How it applies
      Context: the treatments have increased survival.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      1fd62c1ddd41f65aceb23e6c727e3a74174e9abddfb6e23d988bce38d5a34e2c
      Reuse basis
      PMC Open Access subset article under the Creative Commons Attribution 4.0 licence (https://creativecommons.org/licenses/by/4.0/). The article's own license element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Record details

Record id
cardio:cardiotoxicity-from-cancer-treatment
Content hash
236dbd27bff0068450a0e51859dfce956504cc6ac0bad57b5871f6434113cb8e